当前位置: 首页 >> 检索结果
7981. Treatment Differences in Chronic Heart Failure Patients With Reduced Ejection Fraction According to Blood Pressure.
作者: Jesse F Veenis.;Hans-Peter Brunner-La Rocca.;Gerard C M Linssen.;Marco W F Van Gent.;Arno W Hoes.;Jasper J Brugts.; .
来源: Circ Heart Fail. 2020年13卷5期e006667页
Prescribed dosages of heart failure (HF) therapy in patients with a reduced left ventricular ejection fraction remain lower than guideline recommended. It remains unclear whether systolic blood pressure (BP) influences prescription of HF drugs to HF patients with a reduced left ventricular ejection fraction in a European setting. This study aimed to investigate the role of systolic BP on the prescription rate and actual dose of guideline-recommended HF therapy.
7982. Focal Pulsed Field Ablation for Pulmonary Vein Isolation and Linear Atrial Lesions: A Preclinical Assessment of Safety and Durability.
作者: Jacob S Koruth.;Kenji Kuroki.;Iwanari Kawamura.;William C Stoffregen.;Srinivas R Dukkipati.;Petr Neuzil.;Vivek Y Reddy.
来源: Circ Arrhythm Electrophysiol. 2020年13卷6期e008716页
A novel ablation and mapping system can toggle between delivering biphasic pulsed field (PF) and radiofrequency energy from a 9-mm lattice-tip catheter. We assessed the preclinical feasibility and safety of (1) focal PF-based thoracic vein isolation and linear ablation, (2) combined PF and radiofrequency focal ablation, and (3) PF delivered directly atop the esophagus.
7985. Alcohol Consumption and Cardiovascular Disease: A Mendelian Randomization Study.
作者: Susanna C Larsson.;Stephen Burgess.;Amy M Mason.;Karl Michaëlsson.
来源: Circ Genom Precis Med. 2020年13卷3期e002814页
The causal role of alcohol consumption for cardiovascular disease remains unclear. We used Mendelian randomization (MR) to predict the effect of alcohol consumption on 8 cardiovascular diseases.
7986. Letter by Salata et al Regarding Article, "Utilization of Advanced Cardiovascular Therapies in the United States and Canada: An Observational Study of New York and Ontario Administrative Data".
作者: Konrad Salata.;Mohamad A Hussain.;Mohammed Al-Omran.
来源: Circ Cardiovasc Qual Outcomes. 2020年13卷5期e006569页 7987. Response by Cram et al to Letter Regarding Article, "Utilization of Advanced Cardiovascular Therapies in the United States and Canada: An Observational Study of New York and Ontario Administrative Data".
作者: Peter Cram.;Saket Girotra.;John Matelski.;Maria Koh.;Bruce Landon.;Lu Han.;Douglas S Lee.;Dennis T Ko.
来源: Circ Cardiovasc Qual Outcomes. 2020年13卷5期e006587页 7992. Evolution of Pulmonary Hypertension During Severe Sustained Hypoxia.
作者: Fabian Hoffmann.;Ulrich Limper.;Vlad G Zaha.;Hannes Reuter.;Leonora Zange.;Jeanette Schulz-Menger.;Marc Hein.;Stephan Baldus.;Benjamin D Levine.;Jens Jordan.;Jens Tank.
来源: Circulation. 2020年141卷18期1504-1506页 7997. Identification and Characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population-Based Study.
作者: Alexandre Loupy.;Guillaume Coutance.;Guillaume Bonnet.;Jan Van Keer.;Marc Raynaud.;Olivier Aubert.;Marie-Cécile Bories.;Maud Racapé.;Daniel Yoo.;Jean-Paul Duong Van Huyen.;Patrick Bruneval.;Jean-Luc Taupin.;Carmen Lefaucheur.;Shaida Varnous.;Pascal Leprince.;Romain Guillemain.;Jean-Philippe Empana.;Ryan Levine.;Maarten Naesens.;Jigneh K Patel.;Xavier Jouven.;Jon Kobashigawa.
来源: Circulation. 2020年141卷24期1954-1967页
Cardiac allograft vasculopathy (CAV) is a major contributor of heart transplant recipient mortality. Little is known about the prototypes of CAV trajectories at the population level. We aimed to identify the different evolutionary profiles of CAV and to determine the respective contribution of immune and nonimmune factors in CAV development.
7999. Clinical and Hemodynamic Associations and Prognostic Implications of Ventilatory Efficiency in Patients With Preserved Left Ventricular Systolic Function.
作者: Matthew Nayor.;Vanessa Xanthakis.;Melissa Tanguay.;Jasmine B Blodgett.;Ravi V Shah.;Mark Schoenike.;John Sbarbaro.;Robyn Farrell.;Rajeev Malhotra.;Nicholas E Houstis.;Raghava S Velagaleti.;Stephanie A Moore.;Aaron L Baggish.;George T O'Connor.;Jennifer E Ho.;Martin G Larson.;Ramachandran S Vasan.;Gregory D Lewis.
来源: Circ Heart Fail. 2020年13卷5期e006729页
Ventilatory efficiency (minute ventilation required to eliminate carbon dioxide, VE/VCO2) during exercise potently predicts outcomes in advanced heart failure with reduced ejection fraction, but its prognostic significance for at-risk individuals with preserved left ventricular systolic function is unclear. We aimed to characterize mechanistic determinants and prognostic implications of VE/VCO2 in a single-center dyspneic referral cohort (MGH-ExS [Massachusetts General Hospital Exercise Study]) and in a large sample of community-dwelling participants in the FHS (Framingham Heart Study).
8000. Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.
作者: Brahim Redouane.;Stephen J Greene.;Marat Fudim.;Muthiah Vaduganathan.;Andrew P Ambrosy.;Jie-Lena Sun.;Adam D DeVore.;Steven E McNulty.;Robert J Mentz.;Adrian F Hernandez.;G Michael Felker.;Lauren B Cooper.;Barry A Borlaug.;Eric J Velazquez.;Kenneth B Margulies.;Abhinav Sharma.
来源: Circ Heart Fail. 2020年13卷5期e006758页
The FIGHT (Functional Impact of GLP-1 [glucagon-like peptide-1] for Heart Failure Treatment) trial randomized 300 patients with heart failure with reduced ejection fraction (HFrEF) and a recent hospitalization for heart failure to liraglutide versus placebo. While there was no difference in the primary outcome (rank score of time to death, time to rehospitalization for heart failure, and change in NT-proBNP [N-terminal pro-B-type natriuretic peptide]), there was a significant increase in cystatin C among patients randomized to liraglutide raising concern of adverse renal outcomes. We performed a post hoc analysis of FIGHT to investigate whether liraglutide was associated with worsening renal function (WRF).
|